natgillin/translations-raw huggingface dataset:
If needed, your veterinarian might administer more than one dose of naloxone to your dog.
Po potrebi lahko veterinar da psu več kot en odmerek naloksona.
The veterinary medicinal product should be administered with caution.
Pri dajanju zdravila je potrebna previdnost.
Do not use the veterinary medicinal product in lactating or pregnant bitches or breeding animals.
Ne uporabite zdravila za psice med laktacijo ali brejostjo ali za vzrejne živali.
Do not give a second dose of the veterinary medicinal product.
Ne dajajte drugega odmerka zdravila.
In rare cases, dysphoria and urinary retention have also been observed.
V redkih primerih se lahko pojavita disforija in zadrževanje urina.
If the volume to be administered is greater than 0.5 ml, move the applicator tip at least 2.5 cm from the initial site and apply up to 0.5 ml.
Če je volumen, ki ga je treba dati, večji od 0,5 ml, premaknite aplikacijski nastavek najmanj 2,5 cm vstran od začetnega mesta in nanesite do 0,5 ml. Ponavljajte, dokler pes ni prejel vsega izračunanega volumna.
If needed, re-administer naloxone.
Po potrebi ponovno dajajte nalokson.
If a child orally contacts the application site within 72 hours of application, medical attention should be sought immediately.
Če se otrok dotakne mesta nanosa z usti do 72 uro po nanosu,je treba takoj poiskati zdravniško pomoč.
• very rare (less than 1 animal in 10,000 animals, including isolated reports).
• zelo redki (pojavijo se pri manj kot 1 živali od 10.000 živali, vključujoč posamezne primere).
Priestley Road Basingstoke, Hampshire RG24 9NL United Kingdom
Hampshire RG24 9NL UK
To withdraw the solution from the vial, press the provided syringe tip into the centre of the adaptor and gently turn the syringe approximately ¼ turn clockwise until fully seated.
Za jemanje raztopine iz viale pritisnite konico priložene brizge v sredino adapterja in rahlo zavrtite brizgo v smeri gibanja urinih kazalcev za ¼, dokler trdno ne sede.
Attach the applicator tip to the syringe by turning the applicator tip 1/3 turn clockwise 2.
Pritrdite aplikacijski nastavek na brizgo tako, da ga zavrtiteza 1/3 obrata v smeri gibanja urinih kazalcev.
Site preparation: It is not necessary to clip the hair over the application site.
Priprava mesta nanosa: Nad mestom nanosa ni treba striči dlake.
Dosing device:
Dozirna naprava:
The analgesic effects of the veterinary medicinal product are related to the resulting fentanyl blood concentration achieved following application.
Analgetski učinki tega zdravila so odvisni od koncentracije fentanila v krvi po dajanju.
Store the vial together with the Summary of Product Characteristics (SPC).
Shranjujte vialo skupaj s Povzetkom glavnih značilnosti zdravila.
If your dog weighs more than 20 kg, then it will remain in hospital for at least 48 hours following application of Recuvyra.
Če vaš pes tehta več kot 20 kg, potem bo ostal v bolnišnici najmanj 48 ur po nanosu Recuvyre.
It may be necessary to evacuate air from the syringe back into the vial.
Po potrebi potisnite zrak iz brizge nazaj v vialo.
Unless your dog has thick hair it will not usually be necessary to clip/ shave your dog's hair between the shoulder blades for correct application.
Za pravieln nanos običajno ni potrebno striženje/britje dlake med lopaticama psa, razen če je dlaka gosta.
The product should only be applied by a veterinarian.
Zdravilo naj nanese samo veterinar.
A. MANUFACTURING AUTHORISATION HOLDER(S) RESPONSIBLE FOR BATCH RELEASE
A. IMETNIK DOVOLJENJA ZA IZDELAVO ZDRAVILA, ODGOVOREN ZA SPROŠČANJE SERIJ
NAME OF THE VETERINARY MEDICINAL PRODUCT Recuvyra 50 mg/ml transdermal solution for dogs
IME ZDRAVILA ZA UPORABO V VETERINARSKI MEDICINI Recuvyra 50 mg/ml, transdermalna raztopina za pse
INDICATION(S) Recuvyra controls pain in dogs that have undergone major orthopaedic or soft tissue surgery.
Recuvyra lajša bolečine pri psih, ki prestajajo večje kirurške ortopedske operacije in operacije mehkih tkiv.
Therefore, treated dogs of more than 20 kg body weight have to be kept at the hospital for 48 hours post-application.
Zato je treba zdravljene pse s telesno težo nad 20 kg zadržati v bolnišnici 48 ur po nanosu.
In case of accidental ingestion of the veterinary medicinal product, seek medical advice immediately.
Ob nenamernem zaužitju zdravila takoj poiščite zdravniško pomoč.
Withdrawing the solution from the vial Attaching the applicator tip (see Figure 3):
Pritrjevanje aplikacijskega nastavka (glejte sliko 3):
• Has heart failure, low or high blood pressure, low blood volume, impaired breathing, has a history of epilepsy, non-aged related corneal pathology or has or might have a partial or completely stationary bowel.
• Ima srčno napako, nizek ali visok krvni tlak, nizek volumen krvi, prizadeto dihanje, ima
PACKAGE LEAFLET Recuvyra 50 mg/ml transdermal solution for dogs
NAVODILO ZA UPORABO Recuvyra 50 mg/ml, transdermalna raztopina za pse
Attaching the Applicator Tip
Pritrjevanje aplikacijskega nastavka
SPECIAL STORAGE CONDITIONS Store the broached vial with the adaptor in an upright position.
POSEBNA NAVODILA ZA SHRANJEVANJE Prebodeno vialo z adapterjem shranjujte v pokončnem položaju.
• common (more than 1 but less than 10 animals in 100 animals)
• pogosti (pojavijo se pri več kot 1 toda manj kot pri 10 živalih od 100 živali)
Fertility:
Viala:
The tissues should be discarded immediately following use.
Takoj po uporabi brisače odstranite.
Manufacturer for batch release:
Izdelovalec, odgovoren za sproščanje serij:
Applying gentle, even pressure, press the adaptor onto the vial until it is seated.
Narahlo, z enekomernim pritiskom, potisnite adapter na vialo, da nasede nanjo.
• very common (more than 1 in 10 animals displaying adverse reactions during the course of one treatment)
• zelo pogosti (pojavijo se pri več kot 1 živali od 10 živali med enim zdravljenjem)
Recuvyra should only be used for major surgery that requires opiate analgesia for a duration of at least 4 days.
Posebna opozorila Recuvyra se lahko uporablja samo za večje kirurške operacije, ki zahtevajo trajanje opiatne analgezije
EXPIRY DATE EXP:MM/YYYY Once broached, use by….
DATUM IZTEKA ROKA UPORABNOSTI ZDRAVILA EXP: MM/LLLL
• rare (more than 1 but less than 10 animals in 10,000 animals)
• redki (pojavijo se pri več kot 1 toda manj kot pri 10 živalih od 10.000 živali)
Should subsequent surgery be intended in a dog previously treated with the veterinary medicinal product, a minimum of a 7 day dosing interval must be observed before administering another dose.
Če je treba pri psu, ki mu je bilo že dano zdravilo, izvesti naslednjo kirurško operacijo, morate pred dajanjem naslednjega odmerka narediti najmanj 7-dnevni presledek.
• uncommon (more than 1 but less than 10 animals in 1,000 animals)
• občasni (pojavijo se pri več kot 1 toda manj kot pri 10 živalih od 1.000 živali)
Invert vial and pull back on the syringe plunger until the appropriate volume is withdrawn.
Obrnite vialo na glavo in povlecite bat brizge navzdol, da zajamete potrebni volumen.
Dogs of more than 20 kg bodyweight should remain in the hospital for a minimum of 48 hours following application.
Psi s telesno težo, večjo od 20 kg, morajo ostati v bolnišnici najmanj 48 ur po dajanju.
Store the broached vial with the adaptor in an upright position.
Prebodeno vialo z adapterjem shranite v pokončnem položaju.
10 DATE OF REVISION OF THE TEXT {MM/YYYY}
DATUM REVIZIJE BESEDILA
6.5 Nature and composition of immediate packaging Vial:
6.5 Vrsta ovojnine in vsebina
Do not re-use syringes or applicator tips.
Brizge ali aplikacijski nastavki niso za ponovno uporabo.
D. STATEMENT OF THE MRLs Not applicable.
D. NAVEDBA NAJVIŠJIH DOVOLJENIH KOLIČIN OSTANKOV ZDRAVILA (MRL)
QUANTITY OF THE ACTIVE SUBSTANCE(S) Fentanyl 50 mg/ml
K O LIČINA ZDRA VILN E UČINKO VINE Fentanil 50 mg/l
Polska (Poland)
Hrvatska (Croatia)
Terminal half-life (hrs)
NAVEDBA NAJVIŠJIH DOVOLJENIH KOLIČIN OSTANKOV ZDRAVI (MRL)
fax: +40-21-4023001 Romania
Tel. : +33/(0)1 55 49 35 29 France
London, 03 April 2006 EMEA/CHMP/106563/2006
London, 3. aprila 2006 EMEA/CHMP/106563/2006
A positive opinion was adopted 26 January 2006.
Pozitivno mnenje je bilo sprejeto 26. januarja 2006.
The Reference Member State was Netherlands and the Concerned Member States were Belgium and the United Kingdom.
Referenčna država članica je bila Nizozemska, zadevni državi članici pa Belgija in Združeno kraljestvo.
The differences in section 4.3 and 4.6 were considered to be of serious public health concern.
Ocenjeno je bilo, da razlike v poglavjih 4.3 in 4.6 razlog vzbujajo resne pomisleke v zvezi z javnim zdravjem.
The Rapporteur and Co-Rapporteur appointed were Tomas Salmonson and Eric Abadie, respectively.
Poročevalec oz. soporočevalec sta bila Tomas Salmonson oz. Eric Abadie.
The final opinion was converted into a Decision by the European Commission on 03 April 2006.
Končno mnenje je bilo spremenjeno v odločbo Evropske komisije dne 3. aprila 2006.
These Member States were not been able to reach an agreement in respect of the Mutual Recognition of the Marketing Authorisation granted by the Reference Member State.
Te države članice niso uspele doseči soglasja v zvezi z medsebojnim priznavanjem dovoljenja za promet z zdravilom, podeljenega s strani referenčne države članice.
The United Kingdom referred the reasons for disagreement to the EMEA on 23 August 2005.
Združeno kraljestvo je agenciji EMEA posredovalo razloge za nesoglasje dne 23. avgusta 2005.
The Mutual Recognition Procedure started on 25 May 2005.
Postopek medsebojnega priznavanja se je pričel 25. maja 2005.
The arbitration procedure started on 15 September 2005.
Postopek arbitraže se je pričel 15. septembra 2005.
Section 4.3 and 4.6 of the SPC of the reference product in the UK contains the information that the product is contraindicated in pregnancy, for women capable of childbearing or for nursing mothers.
Poglavji 4.3 in 4.6 SPC referenčnega izdelka v Združenem kraljestvu vsebujeta informacijo, da je izdelek kontraindiciran v nosečnosti, za ženske v rodni dobi ali za doječe matere.
The Marketing Authorisation Holder provided written explanations on 13 October 2005.
Imetnik dovoljenja za promet z zdravilom je posredoval pisna pojasnila 13. oktobra 2005.
The list of the product names concerned is given in Annex I. The scientific conclusions are provided in Annex II, together with the Summary of Product Characteristics in Annex III.
Seznam zadevnih imen izdelkov je podan v Dodatku I. Znanstveni zaključki so podani v Dodatku II, skupaj z dopolnjenim Povzetkom glavnih značilnosti zdravila v Dodatku III.
Significant differences have been identified with regard to the proposed SPC compared to the SPC of the reference product in the UK.
V zvezi s predlaganim Povzetkom glavnih značilnosti zdravila (SPC) so bile prepoznane pomembne razlike v primerjavi s SPC referenčnega izdelka v Združenem kraljestvu.
COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) OPINION FOLLOWING AN ARTICLE 29(2)1 REFERRAL FOR Nifedipine Pharmamatch 30 and 60 mg International Non-Proprietary Name (INN): Nifedipine
ODBOR ZA ZDRAVILA ZA UPORABO V HUMANI MEDICINI (CHMP) MNENJE V ZVEZI Z NAPOTITVIJO IZ ČLENA 29(2)1 ZA Nifedipine Pharmamatch 30 in 60 mg Mednarodno nelastniško ime (INN): nifedipin
During the January 2006 meeting, the CHMP, in the light of the overall data submitted and the scientific discussion within the Committee, was of the opinion that the benefit/risk ratio is favourable for Nifedipine Pharmamatch retard 30 and 60 mg tablets, that the objections raised by United Kingdom should not prevent the granting of a Marketing Authorisation and that the Summary of Product Characteristics, labelling and package leaflet of the Reference Member State should be amended.
Med svojim zasedanjem januarja 2006 je CHMP z ozirom na vse posredovane podatke in znanstveno razpravo v okviru Odbora, sprejel mnenje, da je razmerje med tveganji in koristmi za zdravilo Nifedipine Pharmamatch retard 30 mg in 60 mg tablete ugodno, da naj ugovori, podani s strani Združenega kraljestva, ne preprečijo podelitve dovoljenja za promet z zdravilom, ter da je treba Povzetek glavnih značilnosti zdravila, Označevanje in Navodilo za uporabo referenčne države članice dopolniti.
Nifedipine Pharmamatch 30 and 60 mg prolonged release tablets (nifedipine) is 1,4 - dihydropyridine calcium antagonist used for symptomatic treatment of chronic stable angina pectoris as monotherapy or in combination with a beta-blocker and in the treatment of patients with light to moderate essential hypertension.
Zdravilo Nifedipine Pharmamatch retard 30 mg in 60 mg tablete s podaljšanim sproščanjem (nifedipin) je 1,4-dihidropiridinski zaviralec kalcijevih kanalčkov, namenjen za simptomatsko zdravljenje kronične stabilne angine pektoris v monoterapiji ali v kombinaciji z zaviralcem beta ter za zdravljenje bolnikov z blago do zmerno esencialno hipertenzijo.
Pharmamatch BV submitted applications for mutual recognition of Nifedipine Pharmamatch retard 30 and 60 mg tablets on the basis of the marketing authorisation granted by the Netherlands on 29 November 2004.
Podjetje Pharmamatch BV je predložilo vloge za medsebojno priznavanje dovoljenja za promet, ki ga je 29. novembra 2004 Nizozemska podelila za zdravilo Nifedipine Pharmamatch retard 30 mg in 60 mg tablete.
Do not give this medicine to children or adolescents under 18 years of age.
Otroci in mladostniki Zdravila ne dajajte otrokom ali mladostnikom, mlajšim od 18 let.
Date of first authorisation:
Datum prve pridobitve:
Frequency of the adverse reactions is defined as: very common (≥ 1/10), common (≥ 1/100 to < 1/10), uncommon (≥ 1/1,000 to < 1/100), rare (≥ 1/10,000 to < 1/1,000), very rare (< 1/10,000), not known (cannot be estimated from the available data).
Pogostnost neželenih učinkov je opredeljena kot: zelo pogosti (≥ 1/10), pogosti (≥ 1/100 do < 1/10), občasni (≥ 1/1000 do < 1/100), redki (≥ 1/10.000 do < 1/1000), zelo redki (< 1/10.000), neznana (ni mogoče oceniti iz razpoložljivih podatkov).
This is particularly important if you are taking the following medicines which may interact with Senstend:
To je zlasti pomembno, če jemljete katero od naslednjih zdravil, ki lahko medsebojno deluje z zdravilom Senstend:
What Senstend is and what it is used for
Kaj je zdravilo Senstend in za kaj ga uporabljamo
• Inability to develop or maintain an erection
• nezmožnost doseganja in vzdrževanja erekcije;
However, there may be some exposure in female partners of men treated with Senstend.
Vendar lahko pride do določene izpostavljenosti ženskih partnerk moških, ki se zdravijo z zdravilom Senstend.
In serious cases of overdose, symptoms may include fits, low blood pressure, slowed breathing, stopped breathing and altered heart beat.
V hujših primerih prevelikega odmerjanja lahko med simptome spadajo krči, nizek krvni tlak, upočasnjeno dihanje, zaustavitev dihanja in spremenjen srčni utrip.
There is limited data on the efficacy and safety of Senstend in patients 65 years and over.
Podatki o učinkovitosti in varnosti zdravila Senstend pri bolnikih, starih 65 let in več, so omejeni.
Senstend has no or negligible influence on the ability to drive and use machines.
Zdravilo Senstend nima vpliva ali ima zanemarljiv vpliv na sposobnost vožnje in upravljanja strojev.
Absorption of Senstend in conjunctival tissues has not been determined.
Absorpcija zdravila Senstend v konjunktivalna tkiva ni bila določena.
Symptoms of using too much Senstend are listed below.
Simptomi uporabe prevelikega odmerka zdravila Senstend so navedeni spodaj.
Aim the container away from faces to avoid contact with eyes, nose, mouth and ears.
Vsebnik usmerite stran od obrazov, da preprečite stik z očmi, nosom, usti in ušesi.
Elderly Dosage adjustments are not required in the elderly.
Starejši Pri starejših prilagajanje odmerkov ni potrebno.
• Tingling of the skin around the mouth and numbness of the tongue
• mravljinčenje kože okrog ust in omrtvelost jezika;
The efficacy of Senstend was demonstrated in two multi-centre, multinational, randomised, double-blind, placebo controlled studies, both followed by an open-label phase.
Učinkovitost zdravila Senstend je bila dokazana v dveh multicentričnih, multinacionalnih, randomiziranih, dvojno slepih, s placebom kontroliranih študijah, ki jima je sledila odprta faza.
Human exposure from Senstend is 20-30 fold less than the minimum dose that did not result in tumours and 200 fold less than the minimum dose that did result in tumours.
Izpostavljenost pri ljudeh zaradi zdravila Senstend je 20- do 30-krat manjša od najmanjšega odmerka, ki ni povzročil nastanka tumorjev, in 200-krat manjša od najmanjšega odmerka, ki je povzročil nastanek tumorjev.
Hypersensitivity of the patient or their partner to the active substances or to any of the excipients listed in section 6.1.
Preobčutljivost bolnika ali njegove partnerke na zdravilni učinkovini ali katero koli pomožno snov, navedeno v poglavju 6.1.
Pharmacotherapeutic group: Anaesthetics, amides, ATC code: N01BB20
Farmakoterapevtska skupina: anestetiki, amidi, oznaka ATC: N01BB20
• a high temperature
• visoka telesna temperatura.
EU/1/19/1387/001 EU/1/19/1387/002
EU/1/19/1387//002
Senstend should not come into contact with a damaged ear drum.
Zdravilo Senstend ne sme priti v stik s poškodovanim ušesnim bobničem.
The potential for reduction of sperm motility following the clinical use of the medicinal product can not be excluded; therefore it is not possible to state whether Senstend would prevent pregnancy.
Potenciala za zmanjšanje gibljivosti semenčic po klinični uporabi zdravila ni mogoče izključiti; zato ni mogoče opredeliti, ali zdravilo Senstend preprečuje nosečnost.
The European Medicines Agency has waived the obligation to submit the results of studies with Senstend in all subsets of the paediatric population in primary premature ejaculation (see section 4.2 for information on paediatric use).
Evropska agencija za zdravila je odstopila od zahteve za predložitev rezultatov študij z zdravilom Senstend za vse podskupine pediatrične populacije s primarno prezgodnjo ejakulacijo (za podatke o uporabi pri pediatrični populaciji glejte poglavje 4.2).
Other medicines and Senstend
Druga zdravila in zdravilo Senstend
However this study did not reproduce the circumstances of clinical use, as the concentration of Senstend in direct contact with the sperm would be many fold lower.
Vendar v tej študiji niso poustvarili okoliščin klinične uporabe, saj bi bila koncentracija zdravila Senstend v neposrednem stiku s spermo velikokrat manjša.
Senstend is not indicated for use by women.
Zdravilo Senstend ni indicirano za uporabo pri ženskah.
If you use Senstend with condoms, you may be more likely to be unable to develop or maintain an erection.
Če zdravilo Senstend uporabljate skupaj s kondomi, lahko obstaja večja verjetnost za nezmožnost doseganja in vzdrževanja erekcije.
Senstend is not recommended for use whilst your partner is pregnant unless you use a male condom, as listed above, to prevent exposure of the unborn child.
Uporaba zdravila Senstend ni priporočljiva, če je vaša partnerka noseča, razen če uporabite moški kondom, kot je navedeno zgoraj, da preprečite izpostavljenost nerojenega otroka.
Care should be taken not to allow Senstend to come in contact with the eye, as it may cause eye irritation.
Paziti je treba, da zdravilo Senstend ne pride v stik z očmi, saj lahko povzroči draženje oči.
During the 3 months of the double-blind treatment phase, the geometric mean IELT increased from 0.58 to 3.17 minutes in the Senstend group and from 0.56 to 0.94 minutes in the placebo group.
V času 3-mesečne dvojno slepe faze zdravljenja se je geometrična sredina IELT povečala z 0,58 na 3,17 minut pri skupini, ki je prejemala zdravilo Senstend, in z 0,56 na 0,94 minut pri skupini, ki je prejemala placebo.
For all of the three monthly assessments completed by the subjects, there was a significant difference between Senstend and placebo (p < 0.0001).
Pri vseh od treh mesečnih ocen, ki so jih izpolnili preiskovanci, je prišlo do pomembne razlike med zdravilom Senstend in placebom (p < 0,0001).
The clinically significant increases in IELT were paralleled by significant differences in the IPE scores (p < 0.0001).
Klinično pomembna povečanja IELT so sovpadala z občutnimi razlikami med rezultati IPE (p < 0,0001).
Senstend is a combination of two medicines: lidocaine and prilocaine.
Zdravilo Senstend je kombinacija dveh zdravil (lidokaina in prilokaina).
As a precautionary measure, it is preferable to avoid the use of Senstend during pregnancy unless effective male barrier contraceptive measures are taken in order to avoid potential foetal exposure.
Kot previdnostni ukrep se je bolje izogibati uporabi zdravila Senstend med nosečnostjo, razen če se uporablja učinkovita moška pregradna kontracepcijska metoda, da se prepreči potencialna izpostavljenostploda.
Anaemia related conditions
Stanja, povezana z anemijo
Any barrier contraceptives (e.g. male or female condom), which are made from polyurethane-based material cannot be guaranteed to protect against disease or pregnancy when you are also using Senstend.
Pregradne metode kontracepcije (npr. moški ali ženski kondom), izdelane iz materiala na osnovi poliuretana, ne zagotavljajo zaščite pred boleznimi ali nosečnostjo, kadar sočasno uporabljate zdravilo
Also contains: norflurane
SEZNAM POMOŽNIH SNOVI Vsebuje tudi: norfluran
Adjusted mean change scores (Senstend vs. placebo) at Month 3 were 8.2 vs. 2.2 for the ejaculatory control score, 7.2 vs. 1.9 for the sexual satisfaction score, and 3.7 vs. 1.1 for the distress score.
Prilagojeni rezultati spremembe sredine (zdravilo Senstend v primerjavi s placebom) so bili v 3. mesecu 8,2 v primerjavi z 2,2 za rezultat nadzora nad ejakulacijo, 7,2 v primerjavi z 1,9 za rezultat zadovoljstva s spolnim odnosom in 3,7 v primerjavi z 1,1 za rezultat osebne stiske.
The recommended dose of Senstend is 3 sprays (3 sprays = 1 dose) on the head of the penis before sexual intercourse.
Priporočen odmerek zdravila Senstend je 3 razpršitve (3 razpršitve = 1 odmerek) na glavico penisa pred spolnim odnosom.
Lidocaine and prilocaine are excreted in human milk, but at therapeutic doses of Senstend no effects on the breastfed newborns/infants are anticipated due to active substance transfer from the male patient to his female partner.
Lidokain in prilokain se izločata v materino mleko, vendar pri terapevtskih odmerkih zdravila Senstend ni pričakovati nobenega vpliva na dojene novorojenčke/dojenčke zaradi prenosa zdravilne učinkovine z moškega bolnika na njegovo partnerko.
A study in rats showed that Senstend caused a reduction in sperm motility.
V študiji na podganah so zabeležili, da je zdravilo Senstend povzročilo zmanjšanje gibljivosti semenčic.
The plasma levels of lidocaine and prilocaine in male and female subjects were below the level associated with toxicity (5,000 ng/ml).
Ravni lidokaina in prilokaina v plazmi pri moških in ženskih preiskovancih so bile pod ravnjo, povezano s toksičnostjo (5000 ng/ml).
• failure to ejaculate during sexual intercourse
• nezmožnost ejakulacije med spolnim odnosom;
66.2% of Senstend-treated subjects and 18.8% of placebo-treated subjects achieved a mean IELT > 2 minutes.
66,2 % preiskovancev, ki so prejemali zdravilo Senstend, in 18,8 % preiskovancev, ki so prejemali placebo, je doseglo sredino IELT > 2 minuti.
At each of the three monthly assessments all subjects completed a Premature Ejaculation Profile (PEP) questionnaire relating to perceived control over ejaculation, personal distress related to ejaculation, satisfaction with sexual intercourse, and interpersonal difficulty relating to ejaculation.
Pri vsaki od treh mesečnih ocen so vsi preiskovanci izpolnili vprašalnik profila prezgodnje ejakulacije (PEP) glede osebno opaženega nadzora nad ejakulacijo, osebne stiske v povezavi z ejakulacijo, zadovoljstva s spolnim odnosom in medosebnih težav v zvezi z ejakulacijo.
How to use Senstend
Kako uporabljati zdravilo Senstend